| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 10/27/2010 | EP2243490A1 Insulin nasal powder inhalation |
| 10/27/2010 | EP2243489A2 Therapeutic agent for infections |
| 10/27/2010 | EP2243488A2 Pharmaceutical composition for treating vascular-related diseases comprising peptide |
| 10/27/2010 | EP2242875A1 Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound |
| 10/27/2010 | EP2242838A1 Stem-like cells and method for reprogramming adult mammalian somatic cells |
| 10/27/2010 | EP2242769A2 Cadherin-11 ec1 domain antagonists for treating inflammatory joint disorders |
| 10/27/2010 | EP2242764A2 Methods and compositions related to internalizing rgd peptides |
| 10/27/2010 | EP2242763A1 Anti-bacterial compositions |
| 10/27/2010 | EP2242508A2 Pharmaceutical compositions containing the enzyme cyprosin, an aspartic peptidase from cynara cardunculus and its inclusion in antitumour formulations |
| 10/27/2010 | EP2242507A1 Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease |
| 10/27/2010 | EP2242506A2 Method of treating erythropoietin hyporesponsive anemias |
| 10/27/2010 | EP2242505A2 Glycoconjugation of polypeptides using oligosaccharyltransferases |
| 10/27/2010 | EP2242503A2 Therapeutic peptidomimetic macrocycles |
| 10/27/2010 | EP2242502A1 Synthesis of macrocyclic cancer chemotherapy agents and methods of use |
| 10/27/2010 | EP2242501A2 Therapeutic inhibitors of pai-1 function methods of their use |
| 10/27/2010 | EP2242479A2 Counter-pressure filtration of proteins |
| 10/27/2010 | EP2124640B1 Glucose isomerase for use in the treatment of fructose intolerance |
| 10/27/2010 | EP2021356B1 Hiv vaccine |
| 10/27/2010 | EP1982992B1 Hla-binding peptide, precursor thereof, dna fragment encoding the same and recombinant vector |
| 10/27/2010 | EP1940439B1 Reducing post-operative adhesion formation with intraperitoneal glutamine |
| 10/27/2010 | EP1692160B1 Fgf-5 binding and supported peptides |
| 10/27/2010 | EP1355674B1 Oligo alkylene glycol or polyalkylene glycol-coupled thrombin inhibitors |
| 10/27/2010 | EP1330293B2 Controlled release composition comprising lactic acid polymer, and method of producing the same |
| 10/27/2010 | EP1218509B9 Fibroblast growth factor-like polypeptides |
| 10/27/2010 | EP1119627B1 Ebola virion proteins expressed from venezuelan equine encephalitis (vee) virus replicons |
| 10/27/2010 | EP1112088B1 Method for detecting connective tissue growth factor for diagnosing a renal disorder |
| 10/27/2010 | EP0979101B1 Recombinant canine adenovirus 2 (cav2) containing exogenous dna |
| 10/27/2010 | CN1912141B Identification of genes |
| 10/27/2010 | CN1697839B Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof |
| 10/27/2010 | CN1617742B Methods for treating cancer by using tumor-derived dentrical cell inhibitory factor antagonist in combination with toll-like receptor agonist |
| 10/27/2010 | CN1468256B Purification of HBV antigens for use in vaccines |
| 10/27/2010 | CN101873866A Therapeutic or prophylactic agent, detection method and detection agent for metabolic syndrome, and method for screening of candidate compound for therapeutic agent for metabolic syndrome |
| 10/27/2010 | CN101873865A Use of the sequence encoding the carboxyl-terminal domain of the heavy chain of tetanus toxin as a drug |
| 10/27/2010 | CN101873864A Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response |
| 10/27/2010 | CN101873854A Laminins, derivatives, and compositions including same and method for their therapeutic use |
| 10/27/2010 | CN101873851A Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin |
| 10/27/2010 | CN101873849A Biodegradable implants with controlled bulk density |
| 10/27/2010 | CN101870986A Efficient production method and application of antibacterial peptide plectasin |
| 10/27/2010 | CN101870975A Partridge B-cell activating factor cDNA and cloning method and recombinant application thereof |
| 10/27/2010 | CN101870974A Preparation method of proteinase activated receptors agonist and use thereof |
| 10/27/2010 | CN101870735A Novel high-glycosylation erythropoietin immune fusion protein |
| 10/27/2010 | CN101870734A Fusogenic polypeptide for inhibiting neovascularization and coding gene and application thereof |
| 10/27/2010 | CN101870729A Coagulation factor vii polypeptides |
| 10/27/2010 | CN101870728A Novel Exendin variant and conjugate thereof |
| 10/27/2010 | CN101870723A Short peptide and immunosuppressant containing the same and application thereof |
| 10/27/2010 | CN101869716A System for monitoring bacterial tumor treatment |
| 10/27/2010 | CN101869714A Therapeutic agent for infections |
| 10/27/2010 | CN101869701A Hepatocyte growth-promoting factor enteric-coated capsule |
| 10/27/2010 | CN101869700A Chinese medicinal oral liquid for treating tumour and preparation method thereof |
| 10/27/2010 | CN101869699A Preparation process of bone peptide soft capsule |
| 10/27/2010 | CN101869574A Application of uabain for enhancing cellular sensitivity of non-small cell lung cancer (NSCLC) |
| 10/27/2010 | CN101869172A Production method of active eel peptide |
| 10/27/2010 | CN101274095B Humic acid detoxification peptide compound preparation and method for preparing the same |
| 10/27/2010 | CN101156872B Compound recipe bone-peptide preparation |
| 10/27/2010 | CN101081215B Conotoxin SO3 nanometer grain composition and method of making the same and the application thereof |
| 10/27/2010 | CN101070542B Intensified tubercle-resisting action of human interleukin 24 |
| 10/27/2010 | CN101044162B GLP-1 analog fusion protein formulations |
| 10/26/2010 | USRE41894 Hepatitis C inhibitor tri-peptides |
| 10/26/2010 | USRE41887 increases or maintains the number of functional cells of a predetermined type in a mammal by killing or inactivating autoimmune cells and re-educating the host immune system; Type 1 diabetes mellitus |
| 10/26/2010 | US7820807 can bind to and stimulate professional and non-professional human antigen-presenting cells, enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells |
| 10/26/2010 | US7820806 in high yields, with native conformation, and/or in soluble form include solubilizing in non-ionic or zwitterionic detergents; comprises polynucleotide encoding a multiple-membrane-spanning CD20 polypeptide |
| 10/26/2010 | US7820794 adding gamma -polyglutarmic acid ( gamma -PGA) and very low concentration glutaraldehyde to a collagen from a pig skin that has gone through a crosslinking process twice to obtain a long-lasting collagen with a uniformly and completely crosslink and a storage time increased by two to three times |
| 10/26/2010 | US7820793 IFN-λ polypeptides and compositions |
| 10/26/2010 | US7820786 Synthetic peptides and uses therefore |
| 10/26/2010 | US7820784 polypeptides that stimulate the formation and cycling of pre-beta high density lipoproteins, promote lipid transport and detoxification, inhibit osteoporosis and atherosclerosis, intensify the activity anticholesterol agents, causing them to be significantly more antiinflammatory at any given dosage |
| 10/26/2010 | US7820722 Comprises a multi-carbon backbone having an at least partially neutralized carboxy or sulfonic functional group and also one or more side chains that have one or more carbon atoms and, optionally, one or more functional groups. |
| 10/26/2010 | US7820706 Inducing ovulation in a female suffering from anovulatory infertility by administering two or more daily doses of at least one aromatase inhibitor |
| 10/26/2010 | US7820689 treating in-stent restenosis, atherosclerosis, by administering dextromethorphan, naloxone, and/or naltrexone |
| 10/26/2010 | US7820688 one effecting opioid analgesia and one effecting local anesthesia, in amounts sufficient to potentiate an antinociceptive response when both compounds are topically administered in a physiologically acceptable topical excipient |
| 10/26/2010 | US7820671 Peptidomimetic protease inhibitors |
| 10/26/2010 | US7820638 Method of applying hyaluronic acid to implant or graft to enhance lubricity and cellular density |
| 10/26/2010 | US7820635 Therapy for cancer; Alzheimer's disease; using Rna sequences; control degradation , block translation of messenger Rna ; transcription product of target gene encoding clusterin |
| 10/26/2010 | US7820626 such as vulvodynia via comprising administering polyarginine; for treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing agents |
| 10/26/2010 | US7820625 water soluble tripeptides/tetrapeptides having isoleucylglycylseryl-, prolylisoleucylglycylseryl-, glycylprolylisoleucylglycylseryl-, glycylprolylisoleucylglycylthreonyl- and glycylprolylisoleucylglycyl- units; ointments, solids |
| 10/26/2010 | US7820624 which bind to human immature dendritic cells; non-viral transfection mixture comprising lipid component, polycationic nucleic acid-binding component, and peptide; gene expression inhibition; kits |
| 10/26/2010 | US7820623 from Orthochirus scrobiculosus scorpion venom; pharmacokinetics improved via conjugation with ethylene oxide-propylene oxide copolymers and immunoglobulins; autoimmune disorders, multiple sclerosis |
| 10/26/2010 | US7820622 based human tetranectin C-type lectin like domains; rheumatoid arthritis, psoriasis or Crohn's disease; vectors, host cell, bioassay |
| 10/26/2010 | US7820621 also targeting tumor cells that express vascular endothelial growth factor neuropilin-1 receptor; radiotherapy; radiopharmaceuticals; treating angiogenesis |
| 10/26/2010 | US7820620 Cripto antagonism of activin and TGF-b signaling |
| 10/26/2010 | US7820619 potentiate antimicrobial functions of leukocytes such as neutrophils; lower inherent mammalian cell toxicities, improved immunogenicity and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum; antibiotic resistance; pharmacokinetics |
| 10/26/2010 | US7820618 Improved lactate (leucine, arginine, methyl pyruvate, and methyl succinate) usage is accomplished through lactate precursors, adrenergic receptor agonists and insulinotropic agents |
| 10/26/2010 | US7820617 Administering peptide to person sensitive to diabetes; measurement, calibration |
| 10/26/2010 | US7820403 Acyltransferase -1 (ACTR-1); for identifying modulators or are useful themselves as compositions for diagnosis and treatment of disease or disorder that arise from malfunction of the regulation of triacylglycerol (triglyceride) and phospholipid biosynthesis e.g. atherosclerosis; cardiovascular disorders |
| 10/26/2010 | US7820390 Methods of and kits and compositions for diagnosing colorectal tumors |
| 10/26/2010 | US7820193 Anticancer agents; prevent forming blood vessels; removal blockage |
| 10/26/2010 | US7820180 Against an antigen-expressing tumor and for inducing an immune response against a sub-dominant epitope of antigen; vaccine has a strain expressing an antigen fused to a truncated LLO protein; cancer vaccines |
| 10/26/2010 | US7820179 conjugated polymer biodrug for use in treating bone disorders likes osteoporosis or osteopenia, bone fracture |
| 10/26/2010 | US7820178 VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents |
| 10/26/2010 | US7820174 T cell receptors and related materials and methods of use |
| 10/26/2010 | US7820172 including a heparin-binding peptide sequence covalently linked to a linker sequence; useful for coating medical devices and as soluble biologics, and as pharmaceutical agents for treating a variety of conditions |
| 10/26/2010 | US7820169 inhibiting the activity of tumor necrosis factor TNF in a patient having rheumatoid arthritis or psoriatic arthritis, by administering a composition comprising an effective amount of human anti-TNF antibody comprising a heavy chain variable region comprising SEQ ID NO:7 and a light chain variable |
| 10/26/2010 | US7820167 IL1-β: a new target for myeloma therapy |
| 10/26/2010 | US7820156 Inhibiting receptor of a cytokine-2 member of the interleukin-1 family as antiinflammatory agent; sepsis, liver,brain, or lung injuries; arthritis, psoriasis, inflammatory bowel disease |
| 10/26/2010 | US7820154 Use of IL-1 antagonists to treat gout |
| 10/26/2010 | US7819908 Compositions and methods for reducing lung volume |
| 10/26/2010 | CA2526893C Inhibition of the expression of huntingtin gene |
| 10/26/2010 | CA2511446C Synthetic peptide analogs for the treatment of cancer |
| 10/26/2010 | CA2398707C C1 inhibitor produced in the milk of transgenic mammals |
| 10/26/2010 | CA2381229C Stabilized g-csf preparations |
| 10/26/2010 | CA2351887C Psca: prostate stem cell antigen and uses thereof |